Benitec Biopharma Inc. reported no revenues for the quarter ended September 30, 2025, consistent with the same period in 2024. Total operating expenses rose to $9.8 million from $5.8 million in the prior year quarter, primarily due to higher general and administrative costs, which increased to $6.4 million from $2.2 million, while research and development expenses decreased slightly to $3.4 million from $3.6 million. The net loss attributable to shareholders was $9.0 million, or $(0.22) per basic and diluted share, compared to $5.1 million, or $(0.18) per basic and diluted share in the previous year. Cash and cash equivalents stood at $94.5 million as of September 30, 2025. In November 2025, Benitec raised approximately $100 million through a public offering of common stock. The company also reported that the FDA granted Fast Track Designation for its BB-301 candidate in Oculopharyngeal Muscular Dystrophy, following positive interim clinical study results.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-283351), on November 14, 2025, and is solely responsible for the information contained therein.
Comments